All databases comprised pregnant women with T2DM and their infants, which, if liveborn, were followed up until the end of the first year
In most cases, procedures for skin laxity after GLP-1 weight loss are considered elective and are not covered by insurance
Collectively, these threshold-attaining and multidimensionally consistent signals provide a foundation for translating biomarker improvements into clinically perceptible benefits in specific populations
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Beyond these two front-runners, next-generation molecules including triple agonists (GLP-1/GIP/glucagon) and GLP-1 + amylin combination therapiesare expected to gain low-to-mid-teens market share in the early 2030s as manufacturing and cardiovascular data mature
